2011
DOI: 10.1158/1538-7445.am2011-3600
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: c-Met is a receptor tyrosine kinase involved in various malignant phenotypes of diverse cancers. The inhibition of VEGF/VEGFR has been established as a standard therapy for several cancers. Therefore, their dual inhibition is considered to be one of most attractive strategy for cancer therapy. However, unexpectedly success of VEGFR inhibitors (VEGFRI) has been concurrently associated with emerging new type toxicities which result in occasional patient's death and requiring drug off period, frequent interruptio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2013
2013

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Because the MTD of TAS-115 was more than 200 mg/kg/d, the safety margin calculated by the ED 50 and the MTD was more than 25-fold. This suggests that TAS-115 is highly potent and has a favorable safety profile in vivo (43). In the human gastric cancer NUGC-4 peritoneal metastasis model, chronic treatment with TAS-115 improved survival and did not have any severe toxic effects.…”
Section: Discussionmentioning
confidence: 91%
“…Because the MTD of TAS-115 was more than 200 mg/kg/d, the safety margin calculated by the ED 50 and the MTD was more than 25-fold. This suggests that TAS-115 is highly potent and has a favorable safety profile in vivo (43). In the human gastric cancer NUGC-4 peritoneal metastasis model, chronic treatment with TAS-115 improved survival and did not have any severe toxic effects.…”
Section: Discussionmentioning
confidence: 91%